Dyadic International Inc
NASDAQ:DYAI

Watchlist Manager
Dyadic International Inc Logo
Dyadic International Inc
NASDAQ:DYAI
Watchlist
Price: 1.75 USD -8.14% Market Closed
Market Cap: 51.8m USD
Have any thoughts about
Dyadic International Inc?
Write Note

Dyadic International Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dyadic International Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Dyadic International Inc
NASDAQ:DYAI
Operating Income
-$6.5m
CAGR 3-Years
20%
CAGR 5-Years
6%
CAGR 10-Years
-3%
Abbvie Inc
NYSE:ABBV
Operating Income
$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.9B
CAGR 3-Years
-3%
CAGR 5-Years
20%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.3B
CAGR 3-Years
17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
13%
CAGR 10-Years
18%
No Stocks Found

Dyadic International Inc
Glance View

Market Cap
51.8m USD
Industry
Biotechnology

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 7 full-time employees. The company went IPO on 2004-11-05. The firm is focused on developing C1 platform for use in human and animal pharmaceutical applications across the world. The C1 platform technology is based on the Myceliopthora thermophila fungus, which the Company named it as C1. The C1 gene expression platform is used in the discovery, development and manufacturing of biologic medicines and vaccines. The C1 technology is a fungal expression system for gene discovery, development, and production of enzymes and other proteins. The C1 technology is commercially available solutions to uptake genes and develop industrial processes to produce volumes of enzymes and other protein products. The firm is also working on COVID-19 related vaccine and antibody opportunities, including COVID-19 vaccine candidate, DYAI-100.

DYAI Intrinsic Value
2.04 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Dyadic International Inc's Operating Income?
Operating Income
-6.5m USD

Based on the financial report for Sep 30, 2024, Dyadic International Inc's Operating Income amounts to -6.5m USD.

What is Dyadic International Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-3%

Over the last year, the Operating Income growth was 21%. The average annual Operating Income growth rates for Dyadic International Inc have been 20% over the past three years , 6% over the past five years , and -3% over the past ten years .

Back to Top